Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays
Detection Principle
ImmunoAssay-Antibody
Target
IgG
Testing Method Category
Mixed
Testing Method
Abbott Architec i2000, Roche cobas, 411 analyzer, LIAISON®XL platform, VIRCLIA® automation system, Euroimmun SARS-CoV-2 IgG, Virotech SARS-CoV-2 IgG ELISA, in-house developed plaque reduction neutralization test (PRNT)
Testing Method - Additional Info
Two commercially available ELISA assays, four automated immunoassays and a plaque reduction neutralization test (PRNT)) focusing on the detection and neutralization capacity of IgG antibodies in follow up serum or plasma samples of individuals with PCR-diagnosed infections with SARS-CoV-2
Reported Performance
sensitivity: 66.7% (Virotech), 75.6% (Elecsys), 77.8% (Abbott), 71.1% (Euroimmun), 75.6% (Liaison, 91.1% (Virclia), 93.3% (PRNT) ; Specificity: 94.6% (Abbott, Liaison, Virotech, PRNT), 91.7% (Elecsys), 93.9% (Virclia), 100% (Euroimmun)
Sample Size
82 samples
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements